| __timestamp | BioCryst Pharmaceuticals, Inc. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 10811000 |
| Thursday, January 1, 2015 | 13047000 | 33001000 |
| Friday, January 1, 2016 | 11253000 | 64936000 |
| Sunday, January 1, 2017 | 13933000 | 99909000 |
| Monday, January 1, 2018 | 29514000 | 127724000 |
| Tuesday, January 1, 2019 | 37121000 | 161524000 |
| Wednesday, January 1, 2020 | 67929000 | 182933000 |
| Friday, January 1, 2021 | 118818000 | 219982000 |
| Saturday, January 1, 2022 | 159371000 | 278139000 |
| Sunday, January 1, 2023 | 213894000 | 309799000 |
Unleashing insights
In the dynamic world of biotechnology, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Ultragenyx Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc., from 2014 to 2023. Over this period, Ultragenyx consistently outpaced BioCryst in SG&A spending, reflecting its aggressive expansion strategy. By 2023, Ultragenyx's SG&A expenses surged by nearly 186% from 2014, reaching approximately $310 million. In contrast, BioCryst's expenses grew by an impressive 2,768%, peaking at around $214 million. This stark difference highlights Ultragenyx's larger scale and broader operational footprint. However, BioCryst's rapid increase in SG&A expenses suggests a strategic pivot towards scaling operations. Understanding these trends offers valuable insights into the financial strategies driving innovation in the biotech sector.
Pfizer Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Ultragenyx Pharmaceutical Inc.
Breaking Down SG&A Expenses: Sarepta Therapeutics, Inc. vs Ultragenyx Pharmaceutical Inc.
Exelixis, Inc. or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Blueprint Medicines Corporation and Ultragenyx Pharmaceutical Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Verona Pharma plc vs Ultragenyx Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
Ultragenyx Pharmaceutical Inc. and Novavax, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.
Mesoblast Limited and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared